Maxim Group analyst Michael Okunewitch maintained a Buy rating on Longeveron (LGVN – Research Report) yesterday and set a price target of $14.00. The company’s shares closed yesterday at $3.08.
Okunewitch covers the Healthcare sector, focusing on stocks such as Mediwound, Citius Pharmaceuticals, and Longeveron. According to TipRanks, Okunewitch has an average return of -26.9% and a 17.50% success rate on recommended stocks.
Currently, the analyst consensus on Longeveron is a Moderate Buy with an average price target of $13.25.
See the top stocks recommended by analysts >>
Based on Longeveron’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $265 thousand and a GAAP net loss of $5.24 million. In comparison, last year the company earned a revenue of $232 thousand and had a GAAP net loss of $4.86 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Longeveron LLC is a biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. It is involved in sponsoring clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS).
Read More on LGVN:
- Longeveron reports Q4 EPS (21c) vs (20c) last year
- Longeveron Inc. Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
- Longeveron to Announce Fourth Quarter and Full Year Financial Results on March 10, 2023
- Longeveron Appoints Wa’el Hashad as Chief Executive Officer
- Longeveron appoints Wa’el Hashad as Chief Executive Officer
